Antirheumatic Agents

"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that are used to treat RHEUMATOID ARTHRITIS.

Descriptor ID	D018501
MeSH Number(s)	D27.505.954.329
Concept/Terms	Antirheumatic Agents Antirheumatic Agents Anti-Rheumatic Drugs Anti Rheumatic Drugs Antirheumatic Drugs Anti-Rheumatic Agents Anti Rheumatic Agents Antirheumatic Drugs, Disease-Modifying Antirheumatic Drugs, Disease-Modifying Antirheumatic Drugs, Disease Modifying DMARD Disease-Modifying, Antirheumatic Second-Line Drugs Disease Modifying, Antirheumatic Second Line Drugs Antirheumatic Disease-Modifying Second-Line Drugs Antirheumatic Disease Modifying Second Line Drugs Disease-Modifying Antirheumatic Drugs Disease Modifying Antirheumatic Drugs Anti-Rheumatic Agents, Non-Steroidal Anti-Rheumatic Agents, Non-Steroidal Anti Rheumatic Agents, Non Steroidal Non-Steroidal Anti-Rheumatic Agents

Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antirheumatic Agents [D27.505.954.329]

Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.

Bar chart showing 134 publications over 21 distinct years, with a maximum of 14 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	1	0	1
2003	2	1	3
2005	2	1	3
2006	2	1	3
2007	4	0	4
2008	3	1	4
2009	5	1	6
2010	3	1	4
2011	3	2	5
2012	9	3	12
2013	12	0	12
2014	5	2	7
2015	12	2	14
2016	12	1	13
2017	10	1	11
2018	4	1	5
2019	7	6	13
2020	6	2	8
2021	2	1	3
2022	2	0	2

Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.

Furst DE, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Kim SH, Bae YJ, Yang GE, Yoo JK, Kay J, Keystone E. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology (Oxford). 2022 Apr 11; 61(4):1385-1395.

View in: PubMed
Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol. 2022 03; 18(3):263-272.

View in: PubMed
Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1114-1124.

View in: PubMed
Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021 12; 80(12):1522-1529.

View in: PubMed
Kay J, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Bae YJ, Yang GE, Yoo JK, Furst DE, Keystone E. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther. 2021 02 05; 23(1):51.

View in: PubMed
Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold LR, Feathers VL, Shadick N, Weinblatt ME, Reed G. The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. J Rheumatol. 2021 12; 48(12):1776-1783.

View in: PubMed
Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, Chatham W, Cohen S, Costenbader K, Gravallese EM, Kalil AC, Weinblatt ME, Winthrop K, Mudano AS, Turner A, Saag KG. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol. 2021 02; 73(2):e1-e12.

View in: PubMed
Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold LR, Richter S, Guerette B, Mease PJ. Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. J Rheumatol. 2021 05; 48(5):693-697.

View in: PubMed
Kremer JM, Reed G, Pappas DA, Harold LR, Kane K, Greenberg J, Winthrop K. Hydroxychloroquine and the risk of respiratory infections among RA patients. RMD Open. 2020 11; 6(3).

View in: PubMed
Kay J, Harigai M, Rancourt J, Dickson C, Melby T, Issa M, de la Torre I, Isaka Y, Cardoso A, Saifan C, Keystone EC, van Vollenhoven RF, Giles JT, Huizinga TW, Kremer JM. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020 10; 6(3).

View in: PubMed

People

Explore

Similar Concepts

Top Journals